Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR9Q4Y)

Drug Name
2-(1H-indol-3-yl)-N,N-dimethylethanamine Drug Info
Synonyms
N,N-Dimethyltryptamine; N,N-DIMETHYLTRYPTAMINE; DIMETHYLTRYPTAMINE; 61-50-7; 3-(2-Dimethylaminoethyl)indole; 2-(3-Indolyl)ethyldimethylamine; N,N-Dimethyl-1H-indole-3-ethylamine; 2-(1H-Indol-3-yl)-N,N-dimethylethanamine; 1H-Indole-3-ethanamine, N,N-dimethyl-; DMT (psychogenic); (psychogenic); UNII-WUB601BHAA; 3-[2-(dimethylamino)ethyl]indole; EINECS 200-508-4; NSC 63795; WUB601BHAA; N,N-dimethyl-1H-Indole-3-ethanamine; BRN 0138259; CHEMBL12420; DEA No 7435; CHEBI:28969; DMULVCHRPCFFGV-UHFFFAOYSA-N; (2-Indol-3-ylethyl)dimethylamine; Indole,; Dimethyltryptamine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
6089
ChEBI ID
CHEBI:28969
CAS Number
CAS 61-50-7
TTD Drug ID
DMR9Q4Y

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Clinical Trial Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 6 receptor (HTR6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LU AE58054 DMWGRQD Schizophrenia 6A20 Phase 3 [5]
SB-742457 DM6L4ZT Alzheimer disease 8A20 Phase 3 [6]
AVN 211 DMVB4OS Schizophrenia 6A20 Phase 2/3 [7]
SYN120 DMDF7XB Parkinson disease 8A00.0 Phase 2 [8]
AVN 101 DMJFLBC Alzheimer disease 8A20 Phase 2 [7]
SYN-120 DMPW0UL Alzheimer disease 8A20 Phase 2 [9]
PF-05212377 DMPVQYR Alzheimer disease 8A20 Phase 2 [10]
AVN 322 DMK2LGM Cognitive impairment 6D71 Phase 2 [6]
SAM-531 DMHVJZ6 Alzheimer disease 8A20 Phase 2 [11]
SUVN-502 DMQD753 Alzheimer disease 8A20 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [13]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [14]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [15]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [16]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [17]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [18]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [19]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [20]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [21]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Opioid receptor sigma 1 (OPRS1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dextromethorphan DMUDJZM Allergic rhinitis CA08.0 Approved [23]
Dextromethorphan Polistirex DMEHCY5 Dry cough MD12 Approved [24]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [25]
AVP-786 DMV1SOR Alzheimer disease 8A20 Phase 3 [26]
ADX N05 DMLBYRA Mood disorder 6A60-6E23 Phase 3 [27]
Igmesine DMH97XA Major depressive disorder 6A70.3 Phase 2 [28]
OPC-14523 DMB1WF3 Bulimia nervosa 6B81 Phase 2 [29]
ANAVEX 2-73 DM67OU4 Alzheimer disease 8A20 Phase 1 [30]
SSR-125047 DMSUFW6 Schizophrenia 6A20 Phase 1 [31]
SA-5845 DM6XZRL Central nervous system disease 8A04-8D87 Phase 1 [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 5-hydroxytryptamine receptor 2A (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [33]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [34]
Paliperidone DM7NPJS Psychotic disorder 6A20-6A25 Approved [35]
Haloperidol DM96SE0 Delirium Approved [35]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [36]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [37]
Olanzapine DMPFN6Y Bipolar depression Approved [38]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [39]
Arsenic DMTL2Y1 N. A. N. A. Approved [40]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [41]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Flavin-containing monooxygenase 3 (FMO3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [42]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [36]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [37]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [43]
Perazine DM2AOTZ Psychotic disorder 6A20-6A25 Approved [44]
Almogran DM7I64Z Migraine 8A80 Approved [45]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [46]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [47]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [48]
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [49]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [50]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [51]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [52]
Chloramphenicol DMFXEWT Bacterial infection 1A00-1C4Z Approved [53]
Capsaicin DMGMF6V Back pain ME84.Z Approved [54]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [55]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [56]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [55]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [51]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [57]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [57]
Etoricoxib DM6A4NW Rheumatoid arthritis FA20 Approved [57]
Capsaicin DMGMF6V Back pain ME84.Z Approved [54]
Hesperetin DMKER83 High blood cholesterol level 5C80.00 Approved [58]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [56]
Nifedipine DMSVOZT Angina pectoris BA40 Approved [59]
Zileuton DMVRIC2 Allergic asthma CA23.0 Approved [60]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [61]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [33]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Inhibitor [2]
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Inhibitor [2]
Opioid receptor sigma 1 (OPRS1) TT5TPI6 SGMR1_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
5-hydroxytryptamine receptor 2A (HTR2A) OTWXJX0M 5HT2A_HUMAN Drug Response [3]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Regulation of Drug Effects [4]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Regulation of Drug Effects [4]
Flavin-containing monooxygenase 3 (FMO3) OT1G2EV3 FMO3_HUMAN Regulation of Drug Effects [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 141).
2 Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994 Feb;51(2):85-97.
3 Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J. 2006 Jan-Feb;6(1):42-51. doi: 10.1038/sj.tpj.6500342.
4 What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse?. Toxicol Lett. 2016 Sep 6;258:55-70. doi: 10.1016/j.toxlet.2016.06.013. Epub 2016 Jun 15.
5 Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
6 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
7 Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
8 Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
9 The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
10 PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
11 Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
12 Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
13 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
14 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
15 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
16 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
17 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
18 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
19 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
20 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
21 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
22 Clinical pipeline report, company report or official report of Lundbeck.
23 Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7.
24 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
25 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
26 Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
27 Clinical pipeline report, company report or official report of SK BioPhamaceuticals.
28 Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther. 2006 Jun;317(3):1307-19.
29 Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88.
30 2011 Pipeline of Anavex.
31 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
32 Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med. 2004 Nov;45(11):1939-45.
33 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
34 Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
35 Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.
36 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
37 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
38 No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. doi: 10.1038/sj.tpj.6500418. Epub 2006 Sep 19.
39 Nephrotoxicity induced by cisplatin is primarily due to the activation of the 5-hydroxytryptamine degradation system in proximal renal tubules. Chem Biol Interact. 2021 Nov 1;349:109662. doi: 10.1016/j.cbi.2021.109662. Epub 2021 Sep 21.
40 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
41 Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod. 2011 Jul;26(7):1813-25.
42 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
43 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
44 Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
45 Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
46 Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos. 2004 Nov;32(11):1247-53. doi: 10.1124/dmd.104.000026. Epub 2004 Jul 30.
47 Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants. J Pharmacol Exp Ther. 2007 Jan;320(1):266-73. doi: 10.1124/jpet.106.112268. Epub 2006 Oct 18.
48 Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin Cancer Res. 2004 Dec 15;10(24):8357-62. doi: 10.1158/1078-0432.CCR-04-1073.
49 Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. OMICS. 2013 Jul;17(7):353-67. doi: 10.1089/omi.2013.0019. Epub 2013 Jun 11.
50 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
51 Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
52 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
53 Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
54 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
55 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
56 Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
57 In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
58 Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
59 Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
60 Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
61 Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.